Tema Etfs LLC Raises Stake in Abbott Laboratories $ABT

Tema Etfs LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 184.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 49,660 shares of the healthcare product maker’s stock after buying an additional 32,217 shares during the period. Tema Etfs LLC’s holdings in Abbott Laboratories were worth $6,651,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Jones Financial Companies Lllp raised its position in Abbott Laboratories by 10.5% in the first quarter. Jones Financial Companies Lllp now owns 348,852 shares of the healthcare product maker’s stock valued at $45,837,000 after purchasing an additional 33,081 shares during the period. Kera Capital Partners Inc. lifted its stake in shares of Abbott Laboratories by 11.3% during the second quarter. Kera Capital Partners Inc. now owns 2,583 shares of the healthcare product maker’s stock worth $351,000 after purchasing an additional 262 shares in the last quarter. HBW Advisory Services LLC boosted its position in shares of Abbott Laboratories by 8.0% in the second quarter. HBW Advisory Services LLC now owns 3,524 shares of the healthcare product maker’s stock worth $479,000 after buying an additional 261 shares during the period. Finally, RB Capital Management LLC grew its stake in shares of Abbott Laboratories by 1.3% in the second quarter. RB Capital Management LLC now owns 40,683 shares of the healthcare product maker’s stock valued at $5,533,000 after buying an additional 518 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ABT shares. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Barclays boosted their target price on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Daiwa Capital Markets upped their target price on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $147.00 price target on shares of Abbott Laboratories in a research note on Thursday, October 16th. Finally, Benchmark began coverage on shares of Abbott Laboratories in a research report on Friday, October 10th. They issued a “buy” rating and a $145.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $147.68.

Abbott Laboratories Trading Down 0.2%

ABT opened at $125.95 on Monday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The stock has a market capitalization of $219.00 billion, a PE ratio of 15.78, a P/E/G ratio of 2.09 and a beta of 0.72. The firm’s fifty day moving average price is $126.13 and its 200 day moving average price is $129.30.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The company had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter in the previous year, the firm earned $1.21 EPS. The company’s revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.0%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.